Verschillende studies hebben de doeltreffendheid en veiligheid van Aubagio^® in alle leeftijdsgroepen aangetoond.^1,2

Met de recente goedkeuring van de pediatrische indicatie voor patiënten vanaf 10 jaar, is Aubagio^® de eerste orale MS-therapie voor eerstelijnsbehandeling van RRMS. Gecombineerd met zijn eenvoud van behandeling maakt Aubagio een betrouwbare partner voor de behandeling van MS.^1-4

1. Oh J. et al. Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies. Journal of Central Nervous System Disease 2021, Vol. 13: 1–11.
2. Kallmann B. A. et al. Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Ther Adv Neurol Disord 2021, Vol. 14: 1–11.
3. P. Vermersch et al. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017. MSRD, Nov 2020, Vol 46, 102521
4. Avis de la HAS de renouvellement d’inscription d’AUBAGIO^® du 02 octobre 2019 disponible sur : www.has-sante.fr
5. Tornatore C. et al. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Frontiers in Neurology. 2022, Vol. 13, Art. 828616.
6. Dissanto G. et al. Association of Disease-Modifying Treatment and Anti-CD20 Infusion TimingWith Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis. 2021. doi:10.1001/jamaneurol.2021.3609
7. Aubagio^® Summary of Product Characteristics, Belgium.
8. Comi G, Miller AE, Benamor M et al. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. Mult Scler. 2019 Jun 7:1-10
9. Freedman MS, Miller AE, Comi G, et al. Outcomes of the TEMSO extension study of teriflunomide: 10.5 years of clinical results. Poster presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 14-17, 2016; London, UK. Poster P692.
10. Comi G, Freedman MS, Kappos L, et al. Effect of teriflunomide on lymphocyte and neutrophil counts: pooled analyses from four placebo-controlled studies. Poster presented at the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)–European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; September 10–13, 2014; Boston, MA. Poster P060.
11. Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97-104.
12. Lorefice L, Fenu G, Gerevini S, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology. 2018;90(2):83-85.
13. Li L, Liu J, Delohery T, Zhang D, Arendt C, Jones C. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. 2013;265:82-90.
14. Li L, Liu J, Delohery T, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells. Poster presented at the 5th Joint Triennial Congress of ECTRIMS/ACTRIMS; October
15. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659- 674.